Librela is an innovative new drug for the alleviation of pain associated with osteoarthritis in dogs. The medication contains a canine monoclonal antibody (mAb) which targets nerve growth factor (NGF). This inhibits NGF-mediated cell signalling which has been demonstrated to provide relief from pain associated with osteoarthritis.
The product is administered by monthly injection and has been proven to reduce pain scores in dogs with osteoarthritis. Current pain relief options mainly involve the use of Non-Steroidal Anti-Inflammatory Drugs and other pain relief medications to be used alongside this are limited. Librela will be another great tool in the veterinary arsenal against pain associated with the disease and should help greatly improve the welfare of affected patients.
The product has only just received a positive opinion for initial marketing on the 9th September 2020 so it will be a while before it is released onto the veterinary market. We will provide more information on the product when it becomes available.
If you have any specific questions regarding Librela please contact our customer services on suppo[email protected].
Written by: Dr. Nick Garside BVetMed MRCVS